Spectrum Pharmaceuticals Announces Initiation of a Required Phase 1 Study of Apaziquone

Spectrum Pharmaceuticals SPPI announced today that the first patient has been dosed in Japan in a Nippon Kayaku sponsored Phase 1 study of apaziquone in bladder cancer. The Phase 1 study is required by the local regulatory authorities and is designed to enroll up to 6 patients and determine the safety and pharmacokinetics of an immediate instillation of apaziquone in the bladder following transurethral resection of bladder tumor, followed by 6 weekly instillations of apaziquone in the bladder, starting week 4.